Protagonist Therapeutics, Inc. Shares Fell 54% Yesterday After Ab
Shares of Protagonist Therapeutics (PTGX) dropped 54% in after-hours trading on Tuesday after announcing it would discontinue phase 2b Propel trial. The pharmaceutical company was conducting a research on a compound called PTG-100 to see if it was a potential treatment for ulcerative colitis. The company’s decision to bring the study to an early halt…